Pengumuman Kemaskini Terbaru untuk Ahli Profesional Kesihatan
-
2026
-
GLP-1 and Dual GLP-1/GIP Receptor Agonists: Risk of Severe Acute Pancreatitis2026-07-22
-
Lamotrigine: Risk of Photosensitivity Reactions2026-07-06
-
Cefazolin: Risk of Kounis Syndrome2026-07-06
-
Aciclovir (Oral/Injectable) and Valaciclovir: Risk of Acute Generalised Exanthematous Pustulosis (AGEP)2026-07-06
-
COLUMVI® (Glofitamab): New Important Identified Risk of Haemophagocytic Lymphohistiocytosis2026-05-25
-
Clindamycin Hydrochloride (Oral Capsules): Risk of Oesophagitis and Oesophageal Ulcer2026-05-13
-
Mesalazine: Risk of Idiopathic Intracranial Hypertension (IIH)2026-05-07
-
Moxifloxacin: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Fixed-Drug Eruption (FDE), and Photosensitivity Associated with Systemic Use2026-04-29
-
Sunitinib: Risk of Hyperammonaemic Encephalopathy2026-04-29
-
CELLCEPT® (Mycophenolate mofetil): New Important Identified Risk – Anaphylactic Reaction2026-03-19
-
Denosumab (Prolia®) and Biosimilars: Multi Vertebral Fractures (MVF) after Discontinuation of Denosumab – Strengthened Warnings2026-03-19
-
Palbociclib: Risk of Venous Thromboembolism2026-02-10
-
Linezolid: Risk of Rhabdomyolysis2026-02-10
-
Vitamin B6 (Pyridoxine): Risk of Peripheral Neuropathy2026-01-27
-
Garcinia Cambogia and Hydroxycitric Acid: Risk of Hepatotoxicity2026-01-27
-
Prescription Opioid: Risk of Oesophageal Dysfunction2026-01-22
-
-
2025
-
Cyclin-Dependent Kinase Inhibitors (CDKIs): Interaction with Statins Leading to Potential Risk of Rhabdomyolysis2025-11-17
-
Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Risk of Persistent Sexual Dysfunction2025-11-14
-
[Updated] Sulfamethoxazole, Trimethoprim (Cotrimoxazole): Risk of Circulatory Shock2025-11-14
-
Amiodarone: Risk of Primary Graft Dysfunction after Heart Transplantation2025-11-14
-
#MedSafetyWeek turns 10! 🎉2025-11-09
-
That’s a wrap on this year’s #MedSafetyWeek campaign! 🎉2025-11-09
-
Monitoring the safety of medicines doesn’t stop once they hit the pharmacy shelves2025-11-08
-
4️⃣ Ways Healthcare Professionals can be #MedSafetyHeroes 💊🌍2025-11-07
-
4️⃣ Ways Patients can be #MedSafetyHeroes 💊🌍2025-11-06
-
Medicines safety starts with you and me 🤝2025-11-05
-
Do you know how to be a #MedSafetyHero? 💪❓2025-11-04
-
#MedSafetyWeek 2025 starts today! 🚀2025-11-03
-
We all have the power to be a #MedSafetyHero 👦🏻👧👩🏾👨🏻👵🏼👴🤰🏻2025-11-03
-
#MedSafetyWeek is almost here - Are you ready? 🙌2025-10-31
-
📣 Jom sertai Majlis Pelancaran #MedSafetyWeek 20252025-10-24
-
Safety Signal Alert: Doxycycline-Fixed Drug Eruption (FDE)2025-10-13
-
Finasteride and Dutasteride: Risk of Suicidal Thoughts2025-09-23
-
PLAQUENIL® (Hydroxychloroquine): Potential Risk of Major Congenital Malformations and New Risks of Phospholipidosis and Aggravation of Myasthenia Gravis Symptoms2025-09-19
-
[Updated] Hydroxychloroquine: 1) Small Increased Risk of Major Congenital Malformations in Children Following in utero Exposure; 2) Risk of Drug-Induced Phospholipidosis; 3) Risk of Aggravation of Myasthenia Gravis2025-09-18
-
Safety Signal Alert: Lamotrigine-Erythema Multiforme (EM)2025-09-17
-
[Updated] Progestogens (Cyproterone Acetate, Medroxyprogesterone Acetate, Chlormadinone): Risk of Meningioma2025-09-17
-
Oral Anticoagulants (Apixaban, Dabigatran, Edoxaban, Rivaroxaban and Warfarin): Risk of Atraumatic Splenic Rupture2025-08-22
-
Valproate (Sodium Valproate, Valproic Acid): Potential Risks to Offspring Following Paternal Exposure, and Male Infertility2025-08-19
-
Rituximab: Risks of Enteroviral Meningoencephalitis and False-Negative Serologic Testing of Infections2025-07-04
-
Angiotensin II Receptor Blockers (ARBs): Risk of Intestinal Angioedema2025-05-28
-
[Updated] Statins: Risk of Inducing or Aggravating Myasthenia Gravis2025-05-27
-
Isotretinoin: Risk of Sacroiliitis and Urethritis2025-05-26
-
Enoxaparin: Risk of Acute Generalised Exanthematous Pustulosis (AGEP)2025-05-21
-
Azathioprine: Risk of Non-Cirrhotic Portal Hypertension (NCPH) / Portosinusoidal Vascular Disease (PVSD)2025-05-20
-
Hydroxychloroquine: Small Increased Risk of Major Congenital Malformations in Children Following in utero Exposure2025-03-04
-
[Updated] Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (Dulaglutide, Liraglutide, Lixisenatide, Semaglutide, and Tirzepatide): Aspiration and Pneumonia Aspiration during General Anaesthesia or Deep Sedation2025-01-21
-
Ethambutol: Risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)2025-01-09
-
-
2024
-
🙏Thanks for Joining #MedSafetyWeek! 💊🌍2024-11-10
-
💊 Medicines Are Continually Monitored to Ensure Their Safety 🔍2024-11-09
-
❓ 5️⃣Questions to Ask Your Patients to Help Prevent Side Effects 💊2024-11-08
-
❓ 5️⃣Questions to Ask Your Healthcare Professional to Help Prevent Side Effects 💊2024-11-07
-
💊 Not All Medicines Are Equal ⚖️2024-11-06
-
Not All Medicines Are Suitable for Everyone 👶👧🏾👦👨🏻👴👵🤰🏻2024-11-05
-
📣 #MedSafetyWeek Starts Today!2024-11-04
-
We’re Ready for #MedSafetyWeek – Are You? ⏱️2024-10-31
-
📆 Join Us Next Week for #MedSafetyWeek!2024-10-28
-
[Updated] 17-Hydroxyprogesterone Caproate (17-OHPC): Cancellation of Product Registration and Product Recall2024-10-14
-
Paracetamol and Fixed Drug Eruption (FDE): Upward Trend of Reports Involving Paediatric Patients2024-10-10
-
Fluconazole: Updates on the Known Risk of Spontaneous Abortion During Pregnancy and Congenital Malformations in Children Exposed to Fluconazole in Utero2024-10-01
-
Pseudoephedrine: Risk of Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS)2024-09-30
-
Safety Signal Alert: Mefenamic Acid-Associated Generalised Bullous Fixed Drug Eruption (GBFDE)2024-09-02
-
Progestogens (Cyproterone Acetate, Medroxyprogesterone Acetate, Chlormadinone): Risk of Meningioma2024-08-26
-
Azacitidine (Injectable Formulation): Risk of Cutaneous Vasculitis2024-08-12
-
17-Hydroxyprogesterone Caproate (17-OHPC): Potential Cancer Risk in Offspring Exposed in Utero and Limited Efficacy Data2024-07-20
-
Hydroxychloroquine: Risk of Sweet’s Syndrome (Acute Febrile Neutrophilic Dermatosis)2024-07-15
-
Anti-Clusters of Differentiation 20 (CD20) Antibodies (Rituximab, Obinutuzumab, Ofatumumab, Ocrelizumab): Risk of Pyoderma Gangrenosum2024-06-28
-
Amoxicillin: Risk of Aseptic Meningitis2024-05-29
-
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors (Dapagliflozin, Empagliflozin, Canagliflozin): Interaction with Lithium (for Therapeutic Use) Leading to Decreased Serum Lithium Concentration2024-05-28
-
[Updated] Olmesartan: Risk of Autoimmune Hepatitis2024-05-06
-
Proton Pump Inhibitors: Risk of Erectile Dysfunction2024-04-30
-
Levetiracetam and Clobazam: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)2024-04-29
-
Hydrochlorothiazide: Risk of Acute Respiratory Distress Syndrome (ARDS)2024-04-18
-
Ciprofloxacin, Moxifloxacin, Levofloxacin and Ofloxacin (Fluoroquinolones) for Systemic Use (Oral and Injection): Risk of Suicidal Behaviours2024-04-17
-
Domperidone: Risk of Psychiatric Withdrawal Events When Used Off-Label for Lactation Stimulation2024-03-12
-
[Updated] Metformin: Risk of Vitamin B12 Deficiency2024-03-04
-
Statins (Atorvastatin, Rosuvastatin, Simvastatin): Interaction with Ticagrelor Leading to Increased Risk of Rhabdomyolysis2024-02-15
-
Imatinib: Risk of Thrombotic Microangiopathy2024-01-22
-
Rivastigmine: Risks of QT Prolongation and Torsade de Pointes2024-01-19
-
-
2023
-
Clomiphene: Risk of Serious Visual Disturbances Potentially Leading to Blindness2023-12-01
-
IMBRUVICA®(Ibrutinib): Package Insert Updates to Dose Modifications for Adverse Reactions and to Special Warnings and Precautions for Use2023-11-30
-
[Updated] Loperamide: Risk of Acute Pancreatitis2023-11-29
-
[Updated] Topiramate: Neurodevelopmental Disorders in Children Exposed to Topiramate during Pregnancy2023-11-29
-
Thanks for Joining #MedSafetyWeek 2023 💖2023-11-12
-
Hi! Are You a Nurse? 🏥2023-11-10
-
Hey, Are You a Doctor? 👨⚕️🏥👩⚕️2023-11-10
-
Concerned About Side Effects? Remember to check 👀 , talk 🗣 , and tell 💬 this #MedSafetyWeek!2023-11-09
-
💊 Medications in Malaysia are Continually Monitored to Ensure Their Safety 🔎2023-11-08
-
Sleep Troubles After Medication 😵? Remember to Report Them 📝2023-11-07
-
Unexpected Side Effects Can Happen Anywhere, at Any Time: Your Report, Patients' Safety 💊2023-11-06
-
📣 #MedSafetyWeek kicks off today!2023-11-06
-
Preparations for #MedSafetyWeek are well underway – are you ready?2023-11-03
-
Get Ready for #MedSafetyWeek 2023!2023-11-01
-
Isotretinoin: Risk of Psychiatric Disorders and Sexual Dysfunction2023-10-13
-
Cephalosporins: Risk of Seizures2023-09-05
-
Valaciclovir: Risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)2023-08-23
-
[Updated] Clindamycin (Systemic): Risk of Acute Kidney Injury2023-08-07
-
Third-Generation Aromatase Inhibitors (Anastrozole; Exemestane; Letrozole): Risk of Tendon Disorders2023-08-02
-
Statins: Risk of Inducing or Aggravating Myasthenia Gravis2023-07-18
-
GLYPRESSIN® (Terlipressin): Serious or Fatal Respiratory Failure and Sepsis/Septic Shock in Patients with Type 1 Hepatorenal Syndrome (Type 1 HRS)2023-06-13
-
Griseofulvin: Risk of Severe Cutaneous Adverse Reactions (SCARs)2023-05-03
-
Comirnaty Vaccine: Risk of Heavy Menstrual Bleeding2023-05-02
-
Azacitidine: Risk of Differentiation Syndrome2023-04-19
-
Off-Label Use of Diclofenac Suppositories to Treat Fever in Children: Potential Risk of Acute Necrotising Encephalopathy of Childhood (ANEC)2023-04-11
-
[Updated] Pholcodine: Risk of Anaphylaxis to Neuromuscular Blocking Agents (NMBAs)2023-03-23
-
Donepezil: Risk of QT Prolongation and Torsade de Pointes2023-01-16
-
-
2022
-
Pneumococcal Polysaccharide Vaccine (23-Valent): Extensive Swelling of Vaccinated Limb2022-12-20
-
Sorafenib: Risk of Thrombotic Microangiopathy (TMA)2022-12-09
-
Hydroxychloroquine and Chloroquine: Risk of Hepatic Impairment2022-12-06
-
😊 Thank you for joining #MedSafetyWeek 💊2022-11-13
-
💊 How Medication Safety Works? 👨⚕️🏥👩⚕️2022-11-11
-
😊 Hey, are you a pharmacist? 💊2022-11-11
-
💫 When you report a suspected side effect from a medicine, we learn more about it 💡2022-11-10
-
🤒 Have you ever experienced a side effect from a medicine? 😵2022-11-09
-
🙋♂️ How Can You Help Us in Making Medicines Safer for Everyone? 🙋2022-11-08
-
Why do We Monitor the Safety of Medicines?🔎2022-11-07
-
#MedSafetyWeek Starts Today! 💊2022-11-07
-
Get Ready for #MedSafetyWeek!2022-11-03
-
Methadone: Risk of Hypoglycaemia2022-11-02
-
Piperacillin: Risk of Haemophagocytic Lymphohistiocytosis (HLH)2022-11-01
-
Iodinated Contrast Media: Risk of Hypothyroidism (Particularly in Newborns and Young Children)2022-10-27
-
Safety Updates on COVID-19 Vaccines: Risk of Tinnitus2022-10-20
-
Labetalol: Risk of Nipple Pain and Raynaud's Phenomenon of the Nipple2022-10-17
-
Sertraline: Risk of Microscopic Colitis2022-10-17
-
Nirmatrelvir/ Ritonavir (PAXLOVID): Risk of Anaphylaxis and Hypersensitivity Reactions2022-10-05
-
Brolucizumab (Pagenax®): Risk of Intraocular Inflammation, Including Retinal Vasculitis and/or Retinal Vascular Occlusion (Updated Recommendations to Minimise the Known Risks)2022-09-29
-
ALECENSA® (Alectinib): Risk of Haemolytic Anaemia (New Warning and Precaution and Dose Modification Guidance)2022-09-28
-
Metformin: Risk of Vitamin B12 Deficiency2022-09-27
-
Corticosteroids (Systemic): Risk of Pheochromocytoma Crisis2022-07-19
-
Chloroquine and Hydroxychloroquine: Risk of Psychiatric Disorders2022-07-19
-
Azathioprine: Risk of Erythema Nodosum2022-07-18
-
Loperamide: Risk of Acute Pancreatitis2022-06-23
-
Empagliflozin: Risk of Tubulointerstitial Nephritis2022-06-20
-
Olmesartan: Risk of Autoimmune Hepatitis2022-06-16
-
MAVENCLAD® (Cladribine): Risk of Serious Liver Injury and New Recommendations About Liver Function Monitoring2022-06-13
-
Safety Updates on COVID-19 Vaccines: Risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) / Thrombosis with Thrombocytopenia Syndrome (TTS)2022-05-17
-
Warfarin: Risk of Anticoagulant-Related Nephropathy (ARN)2022-05-06
-
Hydrochlorothiazide, Chlorthalidone, Indapamide and Acetazolamide: Risk of Choroidal Effusion, Acute Myopia & Acute Angle-Closure Glaucoma2022-05-05
-
Betamethasone (Systemic): Risk of Pheochromocytoma Crisis2022-04-06
-
Tenofovir Alafenamide: Risk of Renal Adverse Effects2022-03-21
-
-
2021
-
Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis Patients: Risk of Major Adverse Cardiovascular Events (MACE) and Malignancies [Excluding Non-Melanoma Skin Cancer (NMSC)]2021-12-31
-
Clindamycin: Risk of Acute Renal Failure2021-12-31
-
Sulfamethoxazole & Trimethoprim (Co-Trimoxazole): Risk of Acute Respiratory Distress Syndrome (ARDS)2021-12-30
-
Decitabine: Risk of Differentiation Syndrome2021-12-14
-
Anastrozole: Risk of Depression2021-11-24
-
#MedSafetyWeek: Working together we can make vaccines better for everyone!2021-11-05
-
#MedSafetyWeek: Always #ReportSideEffects2021-11-02
-
#MedSafetyWeek starts today!2021-11-01
-
Bortezomib: Risk of Guillain-Barré Syndrome and Demyelinating Polyneuropathy2021-10-12
-
Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): Risk of Abnormal Uterine Bleeding2021-10-07
-
Sacubitril/Valsartan: Risk of Psychiatric Events2021-09-09
-
Mycophenolate Mofetil (MMF) and Myocophenolic Acid (MPA): Risk of De Novo Purine Synthesis Inhibitors-Associated Acute Inflammatory Syndrome2021-07-29
-
Oseltamivir: Risk of Haemorrhages2021-07-08
-
Antidepressants (citalopram; desvenlafaxine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine; vortioxetine): Risk of Postpartum Haemorrhage (PPH)2021-04-22
-
TECENTRIQ® (Atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs)2021-04-22
-
Vascular endothelial growth factor (VEGF) inhibitors for systemic use (except application on eyes): Risk of artery dissections and aneurysms2021-04-20
-
Mirtazapine: Risks of (i) Amnesia and (ii) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)2021-04-20
-
Ceftriaxone: Risk of encephalopathy2021-04-20
-
Safety Updates on COVID-19 Vaccine (Comirnaty®)2021-02-17
-
Mesalazine and sulfasalazine: Nephrolithiasis2021-01-29
-
Efavirenz (including combination products): Risk of late onset neurotoxicity2021-01-29
-
Oseltamivir: Thrombocytopenia2021-01-29
-
Clozapine: Risk of serious bowel complications caused by constipation2021-01-29
-
Abiraterone: Risk of hypoglycaemia due to drug interaction2021-01-29
-
Ondansetron: Information updates on risk of birth defects2021-01-20
-
LEMTRADA® (Alemtuzumab): Revised indication, additional contraindications and risk minimisation measures2021-01-20
-
Tumour Necrosis Factor alpha (TNFα): Kaposi’s Sarcoma2021-01-20
-
-
2020
-
Esmya (ulipristal acetate 5 mg): Withdrawal of product registration2020-12-14
-
GILENYA® (fingolimod): New contraindication in pregnant women and in women of childbearing potential who are not using effective contraception2020-09-08
-
Parenteral nutrition containing amino acids and/or lipids: Risk of toxic degradations of ingredients when exposed to light, which may lead to adverse outcomes in paediatric patients less than 2 years of age2020-08-27
-
Propofol: Risk of priapism2020-08-25
-
PLAQUENIL® (hydroxycholoroquine): Risk of QT prolongation and other drug-drug interactions in the context of COVID-19 management2020-08-14
-
Topiramate: Risk of uveitis2020-08-06
-
Insulin: Risk of cutaneous amyloidosis2020-08-06
-
Reminder on the risk of oculogyric crisis with metoclopramide use2020-06-24
-
Domperidone: Restriction of use in paediatric patients less than 12 years of age2020-06-04
-
Proton pump inhibitors: Risk of microscopic colitis2020-05-28
-
Gabapentin: Risk of dysphagia2020-05-28
-
Rocuronium: Kounis syndrome2020-05-12
-
Nintedanib: Ischaemic colitis2020-05-12
-
Guselkumab: Risk of anaphylaxis2020-04-07
-
KYPROLI® (Carfilzomib): (i) Risk of progressive multifocal leukoencephalopathy (PML); (ii) Risk of hepatitis B virus (HBV) reactivation2020-04-06
-
ESBRIET® (Pirfenidone): Drug-Induced Liver Injury (DILI)2020-04-06
-
Esmya (ulipristal acetate 5 mg): Product recall due to potential risk of liver injury2020-04-06
-
Intravenous iron-containing products: Kounis syndrome2020-04-06
-
Nivolumab: Reports of cytomegalovirus (CMV) infection or reactivation2020-04-06
-
MAKLUMAT TERKINI STATUS PRODUK RANITIDINE BERKAITAN IMPURITI N-NITROSODIMETHYLAMINE (NDMA) [Kemaskini:3/3/2020]2020-03-03
-
Sulfasalazine: Interference with dihydronicotinamide-adenine dinucleotide/ dihydronicotinamide-adenine dinucleotide phosphate (NADH/NADPH) reaction assays2020-02-26
-
Ondansetron: Birth defects2020-02-26
-
Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors: Risk of severe lung inflammation2020-02-26
-
MAKLUMAT TERKINI STATUS PRODUK RANITIDINE BERKAITAN IMPURITI N-NITROSODIMETHYLAMINE (NDMA) [Kemaskini:05/12/2019]2020-02-11
-
New safety measure for sodium valproate: (i) Risk of congenital malformation in neonates and neurodevelopmental problems in children exposed to sodium valproate during pregnancy; (ii) Additional educational material for healthcare professionals and patients/caretakers2020-01-21
-
-
2019
-
Retinoids: Updated measures for pregnancy prevention during retinoids use2019-11-26
-
FEBURIC® (febuxostat): Increased risk of cardiovascular death and all-cause mortality in patients treated with febuxostat in the CARES study2019-11-26
-
Soalan-soalan Lazim (FAQ): Impuriti NDMA di dalam Produk Ranitidine2019-11-26
-
SMECTA® (dioctahedral smectite): Not recommended for use in children aged below 2 years and pregnant or breastfeeding women2019-10-30
-
Clopidogrel: Interaction with boosted antiviral Human Immunodeficiency Virus (HIV) therapy leading to insufficient inhibition of platelet aggregation2019-09-03
-
LEMTRADA® (alemtuzumab): (i) Risk of autoimmune hepatitis (ii) Other serious reactions temporally associated with alemtuzumab infusion (iii) Haemophagocytic lymphohistiocytosis2019-09-03
-
Diclofenac (systemic use): (i) Risk of anastomotic leakage and (ii) Risk of Kounis syndrome2019-08-26
-
ACTEMRA® (tocilizumab): New important identified risk of hepatotoxicity2019-08-26
-
IMOVANE® (zopiclone): New restriction of the indication and additional warnings on abuse and dependence2019-06-20
-
TECENTRIQ® (Atezolizumab): A new important identified risk – immune-related myositis2019-06-20
-
Posaconazole: Pseudohyperaldosteronism2019-06-20
-
Deferiprone: Risk of neurological disorders in children2019-06-12
-
DARZALEX (daratumumab): New identified risk of Hepatitis B Virus reactivation2019-06-12
-
BENLYSTA® (belimumab): Increased risk of serious psychiatric events2019-06-12
-
MADRAC Bulletin - 01/2019 Edition2019-05-29
-
Kenyataan Akhbar KPK 29 Mac 2019 -Produk Losartan yang ditarik Balik di Singapura Serta Situasi di Pasaran Malaysia2019-04-12
-
Kenyataan Akhbar KPK 5 April 2019 – Panggil Balik ke atas Produk Tradisional Mengandungi Paras Logam Berat yang Tinggi2019-04-09
-
Carbimazole and methimazole (thiamazole): (i) Risk of birth defects and neonatal disorders in case of exposure during pregnancy; (ii) Risk of pancreatitis2019-04-09
-
Oral retinoids: Risk of neuropsychiatric symptoms2019-04-04
-
Tapentadol: Risk of seizures and reports of serotonin syndrome when co-administered with other drugs2019-04-04
-
Kenyataan Akhbar KPK 18 Mac 2019 – Produk Tradisional Nan Bao Capsule Dikesan Mengandungi Racun Berjadual Sildenafil Dan Tadalafil2019-03-18
-
Xylometazoline: Increased risk of serious ventricular arrhythmia in patients with long QT syndrome2019-03-15
-
Direct-Acting Antivirals (DAAVs) : Risk of hypoglycaemia in patients with diabetes2019-03-15
-
Kenyataan Akhbar Kementerian Kesihatan Malaysia : Produk Tradisional Nan Bao (Capsule) Dikesan Mengandungi Racun Berjadual Sildenafil2019-02-12
-
Lamotrigine: Risk of hemophagocytic lymphohistiocytosis (HLH)2019-01-31
-
Ceftriaxone: Disturbed consciousness, convulsions or involuntary movements2019-01-31
-
Beta-Lactam antibiotics: Severe Cutaneous Adverse Reactions (SCARs)2019-01-31
-
Acetazolamide: A new contraindication during pregnancy2019-01-31
-
EPILIM® (Sodium Valproate): Important new restrictions on use2019-01-31
-
-
2018
-
New Publication: MADRAC Bulletin - Issue 2/20182018-12-24
-
Fluoroquinolones: Risk of aortic aneurysm and dissection2018-12-19
-
Direktif untuk semua produk yang mengandungi pemetrexed: Pengemaskinian sisip bungkusan dengan maklumat keselamatan berkaitan nephrogenic diabetes insipidus dan renal tubular2018-12-10
-
Direktif untuk semua produk yang mengandungi filgrastim, pegfilgrastim dan lenograstim: Pengemaskinian sisip bungkusan dengan maklumat keselamatan berkaitan aortitis.2018-12-10
-
Direktif untuk semua produk yang mengandungi domperidone: Pengemaskinian sisip bungkusan dan risalah maklumat ubat untuk pengguna (RiMUP) dengan maklumat berkaitan interaksi ubat yang mengakibatkan peningkatan risiko QT interval prolongation.2018-12-10
-
Produk Valsartan Dan Losartan Yang Ditarik Balik Di Amerika Syarikat Serta Situasi Di Pasaran Malaysia2018-11-23
-
Succinylated gelatin (modified fluid gelatin): Possible cross-reactions involving the allergen galactose-alpha-1,3-galactose (Alpha-gal)2018-10-26
-
TIVICAY® (dolutegravir): Reports of neural tube defects2018-10-26
-
XGEVA® (denosumab): Risk of new primary malignancy2018-10-26
-
Eltrombopag: Risk of interference with bilirubin and creatinine test results2018-10-26
-
TECENTRIQ® (Atezolizumab): Risk of nephritis2018-10-26
-
ESMYA® (ulipristal acetate): New contraindication, restricted indication and liver function monitoring requirement2018-10-26
-
MADRAC Bulletin - Issue 02/20182018-10-15
-
Direktif Untuk Semua Produk Yang Mengandungi Iodinated Contrast Media: Pengemaskinian Sisip Bungkusan Dengan Maklumat Keselamatan Berkaitan Severe Cutaneous Adverse Reactions (SCARs)2018-07-26
-
Direktif Untuk Semua Produk Yang Mengandungi Azithromycin, Clarithromycin, Erythromycin Dan Roxithromycin: Pengemaskinian Sisip Bungkusan Dan Risalah Maklumat Ubat Untuk Pengguna (RiMUP) Dengan Maklumat Keselamatan Berkaitan Severe Cutaneous Adverse React2018-07-26
-
Direktif Untuk Semua Produk Yang Mengandungi Doxycycline: Pengemaskinian Sisip Bungkusan Dan Risalah Maklumat Ubat Untuk Pengguna (RiMUP) Dengan Maklumat Keselamatan Berkaitan Jarisch-Herxheimer Reaction2018-06-27
-
Direktif Untuk Semua Produk Yang Mengandungi Prednisone Dan Prednisolone (Kecuali Persediaan Topikal): Pengemaskinian Sisip Bungkusan Dan Risalah Maklumat Ubat Untuk Pengguna (RiMUP) Dengan Maklumat Keselamatan Berkaitan Scleroderma Renal Crisis2018-06-27
-
Direktif Untuk Semua Produk Yang Mengandungi Efavirenz: Pengemaskinian Sisip Bungkusan Dan Risalah Maklumat Ubat Untuk Pengguna (RiMUP) Dengan Maklumat Keselamatan Berkaitan Qtc Prolongation2018-06-27
-
Direktif Untuk Semua Produk Yang Mengandungi Acetazolamide: Pengemaskinian Sisip Bungkusan Dan Risalah Maklumat Ubat Untuk Pengguna (RiMUP) Dengan Maklumat Keselamatan Berkaitan Severe Cutaneous Adverse Reactions (SCARs)2018-06-27
-
Acetazolamide: Risk of Severe Cutaneous Adverse Reactions (SCARs)2018-06-25
-
Drug interaction of oral contraceptives containing ethinylestradiol with the direct-acting antiviral combinations of paritaprevir, ritonavir and ombitasvir with or without dasabuvir2018-06-16
-
ESMYA® 5 mg tablets (ulipristal acetate): Women taking Esmya® for uterine fibroids to have regular liver tests while safety review is ongoing; do not initiate treatment in new patients or those who have completed a previous treatment course2018-04-24
-
Direktif untuk semua produk yang mengandungi mesalazine: Pengemaskinian sisip bungkusan dan risalah maklumat ubat untuk pengguna (RiMUP) dengan amaran kesan advers photosensitivity.2018-04-18
-
Doxycycline: Risk of Jarisch-Herxheimer reaction2018-03-23
-
Gadolinium-based Contrast Agents: Suspension/restriction of use following evidence of gadolinium deposits in the brain after magnetic resonance imaging (MRI) body scans2018-03-23
-
Intravenous (IV) fluids containing electrolytes and/or carbohydrates: Risk of hyponatraemia2018-03-23
-
Levetiracetam and methotrexate: Risk of drug-drug interaction2018-03-23
-
Direktif untuk semua produk yang mengandungi amoxicillin termasuk kombinasi: Pengemaskinian sisip bungkusan dan risalah maklumat ubat untuk pengguna (RiMUP) dengan memperkukuhkan maklumat berkaitan Severe Cutaneous Adverse Reactions (SCARs) pada bahagian Side Effect2018-02-28
-
Direktif penambahan kenyataan amaran bagi semua produk yang mengandungi Boswellia spp2018-02-27
-
Direktif untuk semua produk yang mengandungi gabapentin: Pengemaskinian sisip bungkusan dan risalah maklumat ubat untuk pengguna (RiMUP) dengan maklumat keselamatan berkaitan Respiratory Depression2018-02-27
-
OFEV® (nintedanib): Information on severe liver injury and the need for regular monitoring of liver function associated with the use in patients with idiopathic pulmonary fibrosis (IPF)2018-02-22
-
- 2014